Seeking Alpha

Omeros (OMER) trades lower in the post-session after reporting that results from its first Phase...

Omeros (OMER) trades lower in the post-session after reporting that results from its first Phase 3 clinical trial evaluating OMS103HP in patients undergoing arthroscopic knee surgery did not meet endpoints. However, the drug developer said its plans for another study remain on track for the first half of next year. Shares -6.2% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector